Cancer Immunology Research

Papers
(The TQCC of Cancer Immunology Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A Sampling of Highlights from the Literature218
Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells149
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions113
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions102
Correction: Inflammation Mediated by Gut Microbiome Promotes Immune Suppression and Lung Adenocarcinoma Progression94
Transforming the Dark into Light: A Siglec-9 Switch93
Abstract A022: Therapeutic inhibition of TREX1 elicits type I interferon–mediated antitumor immunity with minimal autoimmune toxicity84
Abstract B002: Meta-Analysis of Neoantigens: Insights from the Cancer Epitope Database and Analysis Resource (CEDAR)73
Abstract A018: Targeting PTPN1/PTPN2 with KQ-791 enhances NK cell cytotoxicity during tumor rechallenge73
Abstract PR-10: Leveraging peripheral leukocyte recruitment to improve efficacy and mitigate toxicities following checkpoint blockade68
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment67
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer65
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy64
Host Interactions with Engineered T-cell Micropharmacies62
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer61
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity57
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma55
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies54
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors53
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer51
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens50
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types48
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions47
T-cell Senescence in the Tumor Microenvironment47
A Sampling of Highlights from the Literature46
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response45
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer45
Engineering CD20 CARs with a Twist44
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics44
A Sampling of Highlights from the Literature44
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status42
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses41
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment41
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells41
SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma41
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment41
Antibody-Mediated Inhibition of HLA/LILR Interactions Breaks Innate Immune Tolerance and Induces Antitumor Immunity40
High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation39
A universal boosting strategy for adoptive T cell therapy using a paired vaccine/chimeric antigen receptor37
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers37
Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer36
Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy36
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function36
Circulating Neoantigen- and Viral Oncoprotein–Specific CD8+ T Cells Share a Transcriptional Signature36
Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma35
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects35
KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer35
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes35
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity34
Abstract P011: B cell subsets that correlate with anti-PD-1 resistance in a preclinical model of HPV+ oropharyngeal cancer33
Abstract P027: Extending intratumoral therapeutic durability using a multivalent immunotherapy platform33
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission32
A Sampling of Highlights from the Literature31
Abstract A012: Cancer acquires therapy resistance by converting immune infiltration to exclusion through NK cell-macrophage interactions31
About the Rising Star31
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses30
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates30
CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer29
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry29
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade29
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma29
Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells29
PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation28
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer28
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma28
Abstract IA07: Impact of immunotherapy on COVID-19 immunity: Insights from checkpoint blockade in cancer27
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity27
A Sampling of Highlights from the Literature26
Abstract PR-05: Sumoylation blockade exposes the dark epigenome to drive ZBP1 viral mimicry for cancer immunotherapy26
Abstract P054: Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types26
Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses26
Abstract IA12: Cancer evolution: Chromosomal instability and immune evasion26
Determinants for Antitumor and Protumor Effects of Programmed Cell Death25
Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors25
Reprogramming CD8+ T-cell Branched N- Glycosylation Limits Exhaustion, Enhancing Cytotoxicity and Tumor Killing25
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies25
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling25
Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression24
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells24
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression24
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy23
Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN23
Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer23
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells23
Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade23
A Sampling of Highlights from the Literature22
Cancer Immunology Research: A Decade of Illumination and Innovation22
CD8+ T Cells Keep Their (K+)urrency for Function22
A Metabolic Axis of Immune Intractability22
Translating Science into Survival: Report on the Seventh International Cancer Immunotherapy Conference22
A Sampling of Highlights from the Literature22
Abstract B003: Oncolytic VSVd51-LIGHT and folfirinox chemotherapy increases anti-tumor immune response in pancreatic ductal adenocarcinoma21
Single-Cell Clonal Lineage Tracing Identifies the Transcriptional Program Controlling the Cell-Fate Decisions by Neoantigen-Specific CD8+ T Cells21
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors21
Pan-cancer single-cell RNA sequencing analysis refines multi-origin monocyte and macrophage lineages21
Abstract B011: Mast cells mediate tumor-suppressive effects in head and neck cancer through immune-microenvironmental regulation21
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells21
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma20
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming20
Antitumor Immune Responses in B2M -Deficient Cancers20
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target20
Abstract IA20: What does not kill it makes it stronger: Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy20
About the Rising Star20
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells20
Regulatory Considerations for Genome-Edited T-cell Therapies20
A Sampling of Highlights from the Literature20
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Effi19
The PO4-tential for Less Toxic CAR T-cell Therapies19
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors19
Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity19
Abstract IA03: Therapeutic modulation of nucleic acids-induced immune activation19
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors19
Abstract P057: Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas18
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer18
A “Function-First” Approach to Identify Regulatory T cell–Targeting Antibodies for Immunotherapy18
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors18
Immunotherapy Inhibits Tumor Cholesterol Synthesis via the IFN-γ-ΙRF1-SREBF2 Axis18
Abstract B022: Investigating Biased GPCRs Activation by Nutraceutical Caffeine and Nicotine in Transactivating Glycosylated Receptors to Induce EMT in Cancer Metastasis18
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides18
CD206+CD14− Skin-Resident Macrophages and DC–T Cell Clusters Are Spatial Features Characterizing Nonrelapsing Cutaneous Squamous Cell Carcinoma18
Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy17
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function17
The Pellino1–PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function17
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation17
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy17
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer17
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts17
The CCL17-CCR4 axis is critical for mutant STAT6-mediated microenvironmental remodelling and therapeutic resistance in Relapsed/Refractory Diffuse Large B-cell Lymphoma17
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models16
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory16
Abstract IA06: Chimeric antigen receptor macrophages for the treatment of solid tumors16
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade16
TIME for Endometrial Cancer: Advancements and Challenges in Therapeutic Targets for the Endometrial Cancer Tumor Immune Microenvironment16
Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up16
A Sampling of Highlights from the Literature16
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer16
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer15
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer15
PI3K/Akt Signaling Pathway Regulates CD155 Expression Involved in Resistance to Cancer Immunotherapy15
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway15
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma15
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy15
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma15
Abstract B007: Tissue-Specific B Cell Differentiation Limits Anti-Tumor Efficacy of Radiation and Immunotherapy15
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer15
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer15
Distinct spatially resolved tumor microenvironment trajectories define benefit from ramucirumab plus pembrolizumab in refractory PD-L1+ gastric cancer15
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation15
Abstract IA04: Reprogramming the tumor–immune microenvironment: From stromal circuits to engineered microbial immunotherapies15
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function15
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells14
Abstract IA16: Immune suppression in cancer and strategies for its reversal14
Abstract A005: TAZ-TEAD signaling alters the immune microenvironment of cutaneous melanoma14
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma14
About the Rising Star14
Abstract P062: PI3Kγδ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanized patient-derived xenograft model14
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity14
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain14
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM14
Chronic ISG15 Exposure Accelerates CD8+ T-cell Dysfunction while Increasing PD-1 Blockade Sensitivity in Oral Squamous Cell Carcinoma13
Unlocking the Immune Response in ALK-Rearranged Lung Adenocarcinoma13
Abstract A015: The emerging role of basophils in non-muscle-invasive bladder cancer13
The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy13
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors13
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer13
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice13
Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases12
A Sampling of Highlights from the Literature12
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance12
iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration12
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer12
A Sampling of Highlights from the Literature12
Abstract B027: iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing12
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer12
Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor12
Abstract A023: Myeloid checkpoint blockade potentiates radiotherapy by modulating dendritic cells and reducing Treg-driven immunosuppression12
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids12
Abstract A006: Assessment of EBV DNA methylation to guide antiviral use in EBV-associated lymphoma12
Something Old and Something New to Unleash the Power of Natural Killer Cells against Metastases12
Abstract PR-15: Neuroimmune dysregulation in ovarian cancer: the role of chronic stress on microglial activation and systemic inflammation12
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status12
Abstract A017: Neutrophil extracellular traps reprogram macrophages to an immunosuppressive phenotype in non-small-cell lung cancer12
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer12
The Problem with Syngeneic Mouse Tumor Models12
Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer11
Abstract P076: Humanized anti-αvβ3 antibody engineered to selectively promote macrophage-mediated cancer cell death11
Abstract B004: Route dependent T-cell activation by mRNA cluster therapies11
Abstract B021: Multi-functional telodendrimer nanodrug: Nanocarrier for ovarian cancer treatment and immunomodulator to control inflammation and sensitize the tumor11
Abstract P051: Function of shp-1 and shp-2 phosphatases in T cell-mediated anti-tumor response11
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome11
Abstract PR-12: Single-cell profiling of tumor-infiltrating B cells reveals autoantibody repertoires and potential cross-talk with T cells11
Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience11
Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human canc11
Abstract A003: Identification of immunomodulatory compounds by high-throughput proteomics: Insights from quantification of 1000 proteins in a 20,000 sample screen11
Abstract A004: Modulating chromatin remodeling as a strategy to reverse immune evasion in ovarian cancer11
0.23982691764832